Nocturia - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 34 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nocturia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Nocturia - Pipeline Review, H2 2016', provides an overview of the Nocturia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Nocturia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nocturia
- The report reviews pipeline therapeutics for Nocturia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Nocturia therapeutics and enlists all their major and minor projects
- The report assesses Nocturia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Nocturia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Nocturia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nocturia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nocturia Overview 6
Therapeutics Development 7
Pipeline Products for Nocturia - Overview 7
Nocturia - Therapeutics under Development by Companies 8
Nocturia - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Nocturia - Products under Development by Companies 11
Nocturia - Companies Involved in Therapeutics Development 12
Allergan Plc 12
Astellas Pharma Inc. 13
Vantia Therapeutics 14
Nocturia - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
ASP-7035 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
ASP-7398 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
desmopressin acetate - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
fedovapagon - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Paxerol - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Nocturia - Dormant Projects 30
Nocturia - Product Development Milestones 31
Featured News & Press Releases 31
May 08, 2016: Studies Demonstrate New Options to Help Prevent and Treat Nocturia 31
May 03, 2016: Allergan Presents New Data on SER120 at the American Urological Association Meeting in San Diego 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables

Number of Products under Development for Nocturia, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Nocturia - Pipeline by Allergan Plc, H2 2016 12
Nocturia - Pipeline by Astellas Pharma Inc., H2 2016 13
Nocturia - Pipeline by Vantia Therapeutics, H2 2016 14
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Stage and Target, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Nocturia - Dormant Projects, H2 2016 30